<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01671774</url>
  </required_header>
  <id_info>
    <org_study_id>GM-IMAB-001-04</org_study_id>
    <secondary_id>2011-005509-64</secondary_id>
    <nct_id>NCT01671774</nct_id>
  </id_info>
  <brief_title>Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer</brief_title>
  <acronym>PILOT</acronym>
  <official_title>Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus or the Gastro-esophageal Junction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ganymed Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to assess the immunological effects and their kinetics, the
      safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of
      Interleukin-2 in subjects with advanced gastroesophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>at least 18 months</time_frame>
    <description>Descriptive statistics for treatments will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune cell profile and kinetics</measure>
    <time_frame>at least 18 months</time_frame>
    <description>Descriptive statistics for treatments will be given on the number and activity of immune cells in peripheral blood of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at least 18 months</time_frame>
    <description>PFS is defined as the time from registration of therapy to the first observation of disease progression or death from any cause or last tumor evaluation if free of progression. For patients who have not progressed either clinically or on the last scan, they will be censured as of the last tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (ORR)</measure>
    <time_frame>at least 18 months</time_frame>
    <description>ORR comprises the fraction of patients with CR, PR according to RECIST v1.1. It is set in relation to the ITT population and PP population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>at least 18 months</time_frame>
    <description>DCR is defined as the fraction of patients with CR or PR or SD according to RECIST v1.1. It is set in relation to the ITT population and PP population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>at least 18 months</time_frame>
    <description>Duration of response is determined as the time when criteria for CR, PR, and SD are first met until the first date that recurrent or progressive disease or death occurs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>CLDN18.2-positive Gastric Adenocarcinoma</condition>
  <condition>CLDN18.2-positive Adenocarcinoma of Esophagus</condition>
  <condition>CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction</condition>
  <arm_group>
    <arm_group_label>IMAB362 + ZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IMAB362 + ZA + IL-2 (1 million IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IMAB362 + ZA + IL-2 (3 million IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IMAB362</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMAB362</intervention_name>
    <description>800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle</description>
    <arm_group_label>IMAB362 + ZA</arm_group_label>
    <arm_group_label>IMAB362 + ZA + IL-2 (1 million IU)</arm_group_label>
    <arm_group_label>IMAB362 + ZA + IL-2 (3 million IU)</arm_group_label>
    <arm_group_label>IMAB362</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>4 mg on d 1 of cycle 1 and cycle 3</description>
    <arm_group_label>IMAB362 + ZA</arm_group_label>
    <arm_group_label>IMAB362 + ZA + IL-2 (1 million IU)</arm_group_label>
    <arm_group_label>IMAB362 + ZA + IL-2 (3 million IU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2 (1 million IU)</intervention_name>
    <description>1 million IU on day 1, 2 and 3 of cycles 1 and 3.</description>
    <arm_group_label>IMAB362 + ZA + IL-2 (1 million IU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2 (3 million IU)</intervention_name>
    <description>3 million IU on day 1, 2 and 3 of cycles 1 and 3.</description>
    <arm_group_label>IMAB362 + ZA + IL-2 (3 million IU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the stomach, the esophagus or the
             gastroesophageal junction

          -  Inoperable locally advanced disease, resections with R0, R1 or R2 outcome or
             metastatic disease.

          -  CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor
             tissue sample.

          -  Measurable and/or non-measurable disease as defined according to RECIST v1.1

          -  Age ≥ 18 years

          -  Written informed consent

          -  ECOG performance status (PS) 0-1

          -  Life expectancy &gt; 3 months

        Exclusion Criteria:

          -  Prior hypersensitivity reaction or intolerance to one of the compounds of the study
             treatment

          -  Known HIV infection or known symptomatic hepatitis (A, B, C)

          -  Clinical symptoms of cerebral metastases

          -  Pregnancy or breastfeeding

          -  Patients treated with any bisphosphonate-based therapeutic for any indication during
             the previous year

          -  Hypocalcemia that requires medication. Corrected (adjusted for serum albumin) serum
             calcium &lt; 8 mg/dl (2 mmol/L) or &gt; 12 mg/dL (3.0 mmol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Klinische Forschung, Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAG / Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin - CVK, Med. Klinik m.S. Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg University Medical Center, Department of Internal Medicine II, Gastroenterology and Hepatology</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig University Hospital, University Cancer Center (UCCL)</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Department of Internal Medicine I - Gastroenterology, Hepatology, Infectious Diseases</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital, Center for Internal Medicine</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piejuras Hospital, Oncology Clinic</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East University Hospital, LLC, Latvian Oncology Center</name>
      <address>
        <city>Riga</city>
        <zip>LV1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2012</study_first_submitted>
  <study_first_submitted_qc>August 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2012</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

